Daniel K. Spiegelman
Spiegelman most recently stepped down as EVP and CFO of BioMarin Pharmaceuticals Inc. after eight years. He remains as a senior advisor until September, 2020. His career at BioMarin spanned 17 years. He served as a CFO in several diversified biotechnology companies over the past 30 years.
- 2020 Third Quarter
Added to: Myriad Genetics Inc. - Salt Lake City, UT
Myriad Genetics is a molecular diagnostic company. Revenues are $835 million.